 The stock price of BeiGene, a biotechnology company focused on developing molecularly targeted and immuno-oncology drug candidates, has seen a rise of 46 over the last twenty-one trading days, while it is up 54 year-t0-date. The recent rise in the stock can be attributed to the U.S. FDAs. 